Medtronic (NYSE:MDT) Price Target Lowered to $110.00 at Citigroup

Medtronic (NYSE:MDT) had its price objective cut by Citigroup from $117.00 to $110.00 in a research report released on Tuesday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical technology company’s stock.

Other equities analysts also recently issued reports about the company. Robert W. Baird lowered their price objective on Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Piper Sandler decreased their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research note on Wednesday, April 1st. Truist Financial decreased their target price on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. Needham & Company LLC restated a “buy” rating and set a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Finally, Daiwa Securities Group decreased their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.10.

Medtronic Stock Performance

Shares of Medtronic stock opened at $86.40 on Tuesday. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company has a market cap of $110.92 billion, a PE ratio of 24.07, a P/E/G ratio of 2.24 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The business has a 50-day simple moving average of $93.90 and a 200-day simple moving average of $96.13.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period in the previous year, the company posted $1.38 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic’s payout ratio is currently 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after buying an additional 1,888,381 shares during the last quarter. State Street Corp lifted its stake in Medtronic by 2.0% in the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after buying an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Medtronic by 2.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after buying an additional 1,419,730 shares during the last quarter. Capital Research Global Investors lifted its stake in Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after buying an additional 3,880,174 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Medtronic by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after buying an additional 231,919 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Citi trimmed its price target to $110 but maintained a Buy rating, signaling continued analyst conviction and meaningful upside vs. current levels. Citigroup Raises/Remains Positive on MDT
• Positive Sentiment: Evercore lowered its target to $108 but kept an Outperform rating, also implying multi‑ten‑percent upside and signaling confidence in MDT’s medium‑term fundamentals. Evercore Adjusts MDT PT
• Positive Sentiment: Argus reduced its target to $115 but retained a Buy rating, another vote of confidence that leaves sizable upside from current levels. Argus Maintains Buy on MDT
• Positive Sentiment: Market research projects steady long‑term growth (5.9% CAGR) in the global lung cancer surgery market — a tailwind for device makers like Medtronic that supply minimally invasive and robotic-assisted tools. This supports longer‑term revenue growth outlooks. Lung Cancer Surgery Market Growth
• Neutral Sentiment: Merit Medical’s acquisition of View Point Medical is industry M&A activity but not directly material to Medtronic’s near-term outlook. Merit Medical Acquisition
• Neutral Sentiment: Inogen’s board appointment is unrelated to Medtronic’s business and unlikely to move MDT stock. Inogen Board Appointment
• Negative Sentiment: Stifel cut its price target to $95 and reiterated a Hold, explicitly citing dilution/transaction impacts from the MiniMed/diabetes spin-off and a MiniMed IPO as limiting near‑term upside — a clear near‑term headwind for sentiment. Stifel Lowers MDT Target, Cites MiniMed IPO Effects
• Negative Sentiment: Johnson & Johnson launched a CE‑marked Varipulse Pro pulsed field ablation platform in Europe — increased competition in electrophysiology/ablation could pressure share gains or pricing in those product lines. J&J Varipulse Pro Launch

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).